LIVER FIBROSIS IS THE COMMON RESPONSE to chronic liver injury and is due to the abnormal accumulation of extracellular matrix (ECM). In response to injury, activated hepatic stellate cells (HSCs) proliferate and produce excess amounts of ECM in response to inflammatory cytokines and growth factors (1, 2, 7) . Among these mediators, transforming growth factor-␤ (TGF-␤) is the major profibrogenic cytokine, upregulating the expression of ␣-smooth muscle actin (␣-SMA) and type 1 collagen-␣ (COL1A) synthesis via Smad signaling pathway, while platelet-derived growth factor (PDGF) is a potent mitogen for HSCs via activation of extracellular signal-regulated protein kinase/mitogen-activated protein kinase and phosphoinositide-3-kinase pathways (2) . Currently, inhibition of TGF-␤ and/or PDGF signaling pathways is considered as a promising antifibrotic strategy.
The PDGF ligand family consists of four different types, named PDGF-A, -B, -C, and -D, respectively. During liver injury, PDGF ligands produced by activated HSCs, infiltrating macrophages, Kupffer cells, and biliary epithelial cells stimulate HSCs in an autocrine and paracrine manner (1, 2) . Produced homo-or heterodimerized PDGF ligands (PDGF-AA, -AB, -BB, -CC, and -DD) elicit their biological effects following binding to PDGFR-␣ and PDGFR-␤ tyrosine kinase receptors, which dimerize into either PDGFR-␣␣, -␣␤, or -␤␤, depending on the type of PDGF dimers. Each PDGF-AA and -DD ligand specifically binds to PDGFR-␣␣ and PDGFR-␤␤, respectively, whereas the PDGF-CC chain interacts with isomers of PDGFR-␣␣ and PDGFR-␣␤. PDGF-BB can bind to all three receptors, which likely induces different effects of PDGF isomers on liver fibrosis (2) . HSCs express both PDGFR-␣ and -␤, but only PDGFR-␤ expression is upregulated during HSC activation in vivo and in vitro (9) , and accordingly, activation of PDGFR-␤ plays a major role in liver fibrosis. Thus, PDGFR-␤ binding to PDGF ligands, such as PDGF-B and -D chains, have been speculated as important factors in liver fibrosis (2). However, PDGF-A or PDGF-C transgenic mice develop spontaneous liver fibrosis by upregulating TGF-␤, whereas specific transgenic PDGF-B expression and PDGF-Dtreated HSCs accelerate activation of HSCs without increased levels of TGF-␤, indicating a TGF-␤-independent manner of activation (2, 3) . In addition, TGF-␤1 is reported to increase the mitotic effects of PDGF-BB by upregulating PDGFR-␤ expression in HSCs (1). These findings are suggested to involve TGF-␤/Smad signaling in the induction of PDGFR-␤ expression at the transcriptional level. However, the reversal effect of PDGFR-mediated signaling that may regulate the TGF-␤/Smad pathway remains unclear.
In this issue of American Journal of Physiology-Cell Physiology, Lee et al. (5) provide convincing evidence supporting the significant role of PDGF-C in the progression of liver fibrosis. By using PDGF-C transgenic mice crossed with Smad3-deficient mice, the authors report that these mice show reduced liver fibrosis compared with PDGF-C transgenic mice. Decreased fibrosis is associated with decreased expression of ␣-SMA, COL1A, and connective tissue growth factor (CTGF) without modification of PDGFRs and TGF-␤1 in HSCs. These findings suggest that Smad3 signaling is associated in part with PDGF-C-mediated liver fibrosis and activation of HSCs. In addition, the authors demonstrate that Smad3-deficient HSC showed decreased proliferation in response to PDGF-CC treat- ment compared with HSCs in wild-type mice. Together, these findings postulate that PDGF-C stimulates proliferation and expression of ␣-SMA, COL1A, and CTGF in HSCs through Smad3 (Fig. 1) . The present study undoubtedly provides several insightful findings regarding the crucial roles of PDGF-C in Smad3 signaling of activated HSCs. However, several unanswered questions remain to be addressed. In particular, the authors did not reveal whether activation of the Smad3 signaling pathway was directly or indirectly activated by PDGF-CC. An interesting paper recently addressed a plausible mechanism, indicating that PDGFR-␣ regulates Smad3 signaling by direct binding with TGF-␤ receptor II (6) . This likely reveals the implication of PDGF-C in Smad3 activation due to the activity of PDGF-C binding with PDGFR-␣. Conversely, PDGFR-␤ expression significantly increased in proportion to activation of HSCs in vitro (6), suggesting less importance of PDGF-C ligand and its receptor PDGFR-␣ for the therapeutic targets in patient with liver fibrosis.
Another important question that could not be addressed in the present study, due to premature mortality of PDGF-C transgenic mice, is the possible impact of PDGF-C in hepatocellular carcinoma (HCC). In this regard, PDGF-C, but not PDGFR-␤ in HSCs, has been considered an important factor in the development of HCC (3, 10) . Various anti-PDGF signaling strategies have been developed to inhibit liver fibrosis, including neutralizing antibodies, recombinant soluble PDGFR extracellular domain or aptamers, and tyrosine kinase inhibitors (2) . The present study provides evidence that induction of Smad7 to inhibit PDGF-C-mediated Smad3 activation could also be an interesting strategy.
As neutralization of TGF-␤ is not applicable due to adverse effects, induction of interferon-␥ by direct treatment or activation of hepatic natural killer cells may be useful to inhibit Smad3 signaling due to the well-known effects of interferon-␥ as not only a suppressor against activated HSCs but also an inducer of Smad7 through the STAT1 pathway (4, 8) . Therefore, further investigation on the exact role of interferon-␥ against the PDGF-C-mediated Smad3 signaling pathway is needed at the onset of HCC development from fibrotic liver. In summary, the present study reveals the existence of a novel pathway where inhibition of Smad3 signaling may become a dual therapeutic target for not only PDGF-C-mediated fibrosis but also HCC. 
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